UNSPSC 51372311: Picenadol

This classification denotes an opioid receptor agonist with the molecular formula C16H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TV3535QWTJ, chemically known as phenol, 3-(1,3-dimethyl-4-propyl-4-piperidinyl)-, trans-(+-)- but generally known as picenadol, which bears US NIH Compound Identifier 53077. European Medicines Agency schedules Picenadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09808MIG. The term PICENADOL is an International Non-Proprietary Name.

UNSPSC 51372311 Picenadol is a Commodity code, but state and local procurement activity under this code shows minimal alignment with the picenadol category name. Recent solicitations tagged with this code are acquiring naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products through competitive bidding and cooperative purchasing arrangements. State and local governments use this code to procure pharmaceutical products and drug-related medical supplies for community health initiatives, emergency response programs, and general pharmacy benefit coverage across health departments, county health services, and state health and human services agencies. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances serving state and local facilities (Minnesota Multistate Cooperative Purchasing Alliance). The pharmaceutical procurement appears fragmented across specialized health procurement offices and cooperative vehicles rather than concentrated within a single issuing-body type.

Geographic activity centers on Florida, Texas, and Minnesota based on recent solicitations, with cooperative purchasing extending across multiple participating states. Representative recent opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and the Minnesota Multistate Cooperative Purchasing Alliance RFP S1070000015802, posted January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities with a response deadline of March 26, 2026. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) on April 3, 2026, regarding direct-to-manufacturer prescription programs, signaling state-level interest in alternative pharmaceutical sourcing and supply-chain models. All three solicitations emphasize compliance with FDA requirements, Good Manufacturing Practices, and drug supply chain security standards, with pricing and competitive selection as primary award drivers.